What is the role of chimeric antigen receptor (CAR) T-cell therapy in the treatment of aggressive recurrent non-Hodgkin lymphoma (NHL)?

Updated: Feb 25, 2021
  • Author: Sanjay Vinjamaram, MD, MPH; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

Chimeric antigen receptor (CAR) T-cell therapy is approved for use in adult patients with relapsed or refractory large B-cell lymphoma, after two or more lines of systemic therapy. The following CAR T-cell therapies have FDA approval:

  • Axicabtagene ciloleucel (Yescarta) -  Indications include diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

  • Tisagenlecleucel (Kymriah) - Indications include DLBCL not otherwise specified, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

  • Lisocabtagene maraleucel (Breyanzi) - Indicated for DLBCL not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B. It is not indicated for primary CNS lymphoma.

For full discussion, see Cancer Immunotherapy with Chimeric Antigen Receptor (CAR) T Cells.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!